Insights and articles from the world of life sciences with a focus on current topics in high content imaging, cell biology and pharmaceutical research.
Marc Bickle discusses how Deep Phenotyping and AlphaFold are transforming early-stage drug discovery. Learn about cutting-edge technologies that enhance precision in oncology and neurodegenerative research, offering new insights and accelerating the development of personalized therapies through advanced AI-driven methods and high-content imaging.
Thomas Müller, a distinguished scientist with over 30 years’ experience in ion channel research, talks about his journey from studying biology in Heidelberg and Glasgow to leading high-throughput screening at Bayer, where he’s been at the forefront of scientific innovation. In this enlightening session, Thomas shares his remarkable journey and delves into the fascinating world of ion channels.
In order to better describe the current state and future prospects of High-Content Imaging, a market survey was conducted among researchers and organizations involved in early drug discovery worldwide.
Want to explore the groundbreaking intersection of cell biology and artificial intelligence in drug discovery? I was delighted to have the opportunity to discuss this topic with Niranj Chandrasekaran of the BROAD Institute on January 12, 2024. In this interview, we discussed the transformative role of cell painting and KI technologies in advancing drug discovery.
Join us for an exciting discussion on the use of specialized AI tools in early drug discovery. David Egan, CEO of Core Life Analytics and Philipp Kainz, CEO of KML Vision discuss the use of the latest developments in the field of advanced machine learning and deep learning.
Eugenio Fava, an accomplished scientist known for his passion and deep expertise in neuroscience and drug discovery, will share his insights into the drug discovery process, providing insight into the strategic approaches essential to understanding diseases, identifying key targets, and developing effective drugs using cutting-edge technologies.
In this interview, Philip Kainz, CEO of KML Vision, talks about the development of analysis tools for scientific research.